Delta to produce anti-anthrax drug in Malta

Delta, the Icelandic pharmaceutical development company, will soon be supplying its European markets with the antibiotic Ciprofloxacin manufactured at Pharmamed in Malta.

Delta became full owner of the Maltese pharmaceutical manufacturer following a transfer of shareholding from the Dutch Aid Organisation IDA last summer.

Ciprofloxacin has been in the spotlight over the last month as it is the preferred treatment for Anthrax. Delta has managed to be one of the first suppliers of the generic drug in Germany following the expiry of the patent last August, and shall soon be launching the product in the UK and other European markets. Sales of Delta’s Ciprofloxacin are estimated to reach Lm 3.8 million this year.

Pharmamed has recently completed production trials of Ciprofloxacin and is expected to start manufacturing the product under license early next year. In fact, it is expected that most European markets will be supplied with Delta’s Ciprofloxacin by Pharmamed.

Delta will shortly be submitting its branded product Siprox (Ciprofloxacin) for registration and sale in Malta.